PCOS and Glucose Sensitivity
A recent study carried out by Hoang, V et al (2015) provides early evidence of the beneficial effects of GLP-A agonist in improving glucose sensitivity, abdominal obesity, serum cholesterol and hypertension in an established rat model of PCOS. Liraglutide is a long acting Glucagon-like peptide 1 (GLP-1) receptor agonist. It is FDA approved for treating type 2 diabetes and improves glycaemic control by augmenting insulin secretion from the pancreas . Liraglutide has also been shown to lower blood pressure in patients with type 2 diabetes. Full details of the study can be found here.
PCOS and Nutrition for Symptom Prevention
At the annual meeting of the American Association of Diabetes Educators, presenters A Grassi and Hilary Wright, suggested that all women with PCOS should receive nutrition counselling with a registered dietitian or nutritionist to prevent the onset of diabetes and other chronic diseases associated with the condition. (Wright H, Grassi A. T20 – The Link Between PCOS, Prediabetes and Diabetes: Nutrition Strategies for Prevention. Presented at: AADE 2015; Aug. 5-8, 2015; New Orleans) You can read more about their presentation here.